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Immune-Related Adverse Events Are Associated With Improved
Response, Progression-Free Survival, and Overall Survival
for Patients With Head and Neck Cancer Receiving Immune
Checkpoint Inhibitors
1
Corey C. Foster, MD
; Marcus A. Couey, MD, DDS2; Sara E. Kochanny, BA3; Arun Khattri, PhD3; Rajesh K. Acharya, MS3;
Yi-Hung Carol Tan, PhD3; Ryan J. Brisson, MD4; Rom S. Leidner, MD2; and Tanguy Y. Seiwert, MD5

BACKGROUND: The authors hypothesized that patients developing immune-related adverse events (irAEs) while receiving immune
checkpoint inhibition (ICI) for recurrent/metastatic head and neck cancer (HNC) would have improved oncologic outcomes. METHODS:
Patients with recurrent/metastatic HNC received ICI at 2 centers. Univariate and multivariate logistic regression, Kaplan-Meier methods,
and Cox proportional hazards regression were used to associate the irAE status with the overall response rate (ORR), progression-free
survival (PFS), and overall survival (OS) in cohort 1 (n = 108). These outcomes were also analyzed in an independent cohort of patients receiving ICI (cohort 2; 47 evaluable for irAEs). RESULTS: The median follow-up was 8.4 months for patients treated in cohort 1. Sixty irAEs
occurred in 49 of 108 patients with 5 grade 3 or higher irAEs (10.2%). ORR was higher for irAE+ patients (30.6%) in comparison with
irAE− patients (12.3%; P = .02). The median PFS was 6.9 months for irAE+ patients and 2.1 months for irAE− patients (P = .0004), and the
median OS was 12.5 and 6.8 months, respectively (P = .007). Experiencing 1 or more irAEs remained associated with ORR (P = .03), PFS
(P = .003), and OS (P = .004) in multivariate analyses. The association between development of irAEs and prolonged OS persisted in a
22-week landmark analysis (P = .049). The association between development of irAEs and favorable outcomes was verified in cohort 2.
CONCLUSIONS: The development of irAEs was strongly associated with an ICI benefit, including overall response, PFS, and OS, in 2
separate cohorts of patients with recurrent/metastatic HNC. Cancer 2021;0:1-9. © 2021 American Cancer Society.
KEYWORDS: immune checkpoint inhibitor, immunotherapy, metastasis, squamous cell carcinoma of head and neck, toxicity.

INTRODUCTION
Head and neck cancers (HNCs) represent a significant disease burden, with 66,000 new diagnoses and 15,000 cancer-
related deaths expected in the United States in 2020,1 and the increasing incidence of human papillomavirus (HPV)–
associated oropharyngeal cancer2-4 suggests that the prevalence of HNCs will continue to rise for the foreseeable future.
Contemporary landmark trials5-7 have prompted a paradigm shift toward immunotherapy as an attractive option for
patients with recurrent or metastatic HNC, and it has moved to the first-line setting as standard of care on the basis of the
positive results of KEYNOTE-048. Although the response to anti–programmed death 1 (PD-1) therapy in this setting
appears to be enhanced with increased tumoral expression of programmed death ligand 1 (PD-L1),5,7-9 PD-L1 remains
an imperfect biomarker because tumoral expression is spatially and temporally heterogeneous, and an assessment of
positivity requires an invasive biopsy.10 Therefore, alternative biomarkers, including the tumor mutational burden, gene
expression signatures, and blood-based markers, are being evaluated.9
Because of PD-L1’s drawbacks as a biomarker for responses to immune checkpoint inhibition (ICI), alternative
indicators of immune competence that identify patients most likely to benefit from ICI may be of greater clinical utility.
The search for such optimal biomarkers would likely be most efficient when focused on target populations known to
have favorable responses to ICI. Such biomarkers may indicate with a higher degree of immune competence. Specifically,
the ability to develop immune-related adverse events (irAEs) has been correlated with improved antitumor responses in
patients with various primary malignancies, and this suggests that it could be one such indicator.11-25 Despite these prior
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associations between irAEs and improved outcomes with
ICI, the relationship between irAEs and prognosis is less
clear for patients with HNC. We hypothesized that experiencing irAEs would be associated with an improved
overall response rate (ORR), improved progression-free
survival (PFS), and improved overall survival (OS) for
patients with recurrent or metastatic HNC and thereby
could identify candidate patients with favorable immune
competence for the investigation of meaningful pretreatment biomarkers.
MATERIALS AND METHODS
Patient Population

The medical records of 114 patients (108 evaluable for
their irAE status) with metastatic HNC consecutively
receiving ICI at the University of Chicago from June
17, 2013, to September 29, 2017, were retrospectively
reviewed in an institutional review board–
approved
study. The medical records of an external patient cohort
(n = 47) with metastatic HNC consecutively treated
with ICI from April 28, 2014, to April 12, 2018, at
Providence Cancer Institute were also retrospectively
reviewed with institutional review board approval. All
patients underwent a complete history and physical as
well as baseline diagnostic imaging and laboratory assessments confirming adequate organ and bone marrow
function before they received ICI. Treatments before
ICI was started were diverse and included combinations
of surgery, radiation, chemoradiation, and/or systemic
chemotherapy as deemed appropriate by the treating
physician. Among patients with oropharyngeal cancer
treated at the University of Chicago, 42 had a known
HPV status determined by p16 immunohistochemistry and/or HPV polymerase chain reaction, whereas 17
patients with oropharyngeal primaries from Providence
Cancer Institute had a known HPV status. Furthermore,
78 patients from the University of Chicago had tumor
specimens subjected to tumor PD-L1 immunostaining
using the E1L31 antibody (Cell Signaling, Danvers,
Massachusetts). Tumor PD-L1 expression was assessed,
and positivity was defined as expression in ≥1% of
tumor cells. PD-L1 combined positivity scores were
not assessed or available in either patient cohort, and
the tumor PD-L1 status was not routinely assessed for
patients at Providence Cancer Institute.
Treatment Details

All patients received ICI with anti-
PD(L)1 therapy,
and treatment was independent/unselected for tumor
2

PD-L1 expression. Among University of Chicago patients, ICI included nivolumab for 31 patients, pembrolizumab for 75 patients, and durvalumab for 2
patients, whereas ICI consisted of nivolumab for 29 patients, pembrolizumab for 14 patients, durvalumab for
3 patients, and cemiplimab for 1 patient at Providence
Cancer Institute. Patients were generally continued on
immunotherapy until the development of dose-limiting
toxicity or clinical/radiographic progression. While receiving ICI, patients routinely underwent follow-up, including a physical examination, a laboratory evaluation,
and imaging, to assess for a clinical response as dictated
by individual protocols or clinical judgment, with diagnostic imaging most often performed at a minimum
interval of every 3 months. The best overall response
was determined with the Response Evaluation Criteria
in Solid Tumors (RECIST; version 1.1) for both patient
cohorts. Toxicities were prospectively graded for all patients according to the Common Terminology Criteria
for Adverse Events (version 4.0).
Statistical Analyses

irAEs were considered to be any possibly immune-
mediated adverse events as determined by physician
review, regardless of grade or treatment attribution.
The types, numbers, and grades of irAEs during the
receipt of ICI were summarized with descriptive statistics. Comparisons of patient-and treatment-related
variables were performed via χ2 analysis for categorical variables or via univariate regression for continuous
variables. The relationship between irAE positivity and
a complete or partial response (eg, ORR) by RECIST
(version 1.1) was assessed via univariate and multivariate logistic regression. Kaplan-Meier curves estimated
PFS and OS as a function of the irAE status, with comparisons between groups performed with the log-rank
test. Both PFS and OS were calculated from the start
date of ICI. For multivariate analyses, Cox proportional
hazards regression was used. Factors associated with
PFS and OS (P < .10) in the univariate analysis were
included in multivariate analyses.
To correct for a potential time-
related bias, a
landmark analysis using the Kaplan-Meier method at
22 weeks (5.5 months) was performed for OS. The
22-week landmark time was chosen in an attempt to
balance the risks and benefits associated with a late
landmark potentially lowering the sample size and
an earlier landmark potentially misclassifying a larger
number of patients experiencing irAEs in the analysis.
Furthermore, this was close to the median duration of
Cancer  
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TABLE 1. Patient-and Treatment-Related Characteristics
Entire Cohort (n = 108)

Characteristic
Age, median (range), y
Disease site, No. (%)
Hypopharynx
Larynx
Oral cavity
Oropharynx
Nasal cavity
Unknown primary
Other or multiple sites
Sex, No. (%)
Male
Female
Ethnicity, No. (%)
White
African American
Asian/Mideast Indian
Other
HPV status (oropharynx only), No. (%)
Positive
Negative
Unknown
No. of prior treatments, median (range)
Tobacco use, No. (%)
Yes
No
Unknown
PD-L1 status, No. (%)
Positive
Negative
Unknown

Immune AE (n = 49)

No Immune AE (n = 59)

60 (25-85)

61 (33-85)

59 (25-83)

5 (4.6)
10 (9.3)
29 (26.9)
47 (43.5)
5 (4.6)
4 (3.7)
8 (7.4)

4 (8.2)
6 (12.2)
13 (26.5)
19 (38.8)
2 (4.1)
2 (4.1)
3 (6.1)

1 (1.7)
4 (6.8)
16 (27.1)
28 (47.5)
3 (5.1)
2 (3.3)
5 (8.5)

82 (75.9)
26 (24.1)

38 (77.6)
11 (22.4)

44 (74.6)
15 (25.4)

89 (82.4)
11 (10.2)
5 (4.6)
3 (2.8)

39 (79.6)
7 (14.3)
2 (4.1)
1 (2.0)

50 (84.7)
4 (6.8)
3 (5.1)
2 (3.3)

33 (30.6)
9 (8.3)
5 (4.6)
2 (0-6)

15 (78.9)
3 (15.8)
1 (5.3)
2 (0-5)

18 (64.3)
6 (21.4)
4 (14.3)
2 (0-6)

70 (64.8)
33 (30.6)
5 (4.6)

33 (67.3)
14 (28.6)
2 (4.1)

37 (62.7)
19 (32.2)
3 (5.1)

55 (51.0)
23 (21.3)
30 (27.8)

26 (53.1)
10 (20.4)
13 (26.5)

29 (49.2)
13 (22.0)
17 (28.8)

Pa
.19
.66

.72

.61

.51

.97
.65

.76

Abbreviations: AE, adverse event; HPV, human papillomavirus; PD-L1, programmed death ligand 1.
a
Comparing those with immune AEs and those with no immune AEs.

ICI therapy among irAE+ patients, and previous reports documenting long-
term outcomes for patients
receiving ICI have demonstrated that treatment-related
adverse events are stable after a median time on treatment of 22 weeks.26 A landmark analysis was not performed for the cohort of patients treated at Providence
Cancer Institute because the small sample size limited
statistical inference. All analyses were performed with
JMP Statistical Software (version 13.0; SAS Institute,
Cary, North Carolina).
RESULTS
Patient and irAE Characteristics

The baseline characteristics for all University of Chicago
patients and for irAE+ and irAE− subsets are displayed
in Table 1. A large proportion of the patients were male
(82 of 108 [75.9%]) with a median age of 60 years (range,
25-85 years) and with primary lesions of the oropharynx
(47 of 108 [43.5%]). Most of the patients with oropharyngeal disease and a known HPV status (n = 42) had
HPV-associated tumors (33 of 42 [78.6%]), and these
individuals were similarly distributed in the irAE+/−
groups (P = .51). Furthermore, 78 patients had a known
Cancer  
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tumor PD-L1 status, with 55 (70.5%) being positive for
PD-L1 (47 of 55 with tumor PD-L1 expression of 1%-
49% and 8 of 55 with tumor PD-L1 expression ≥ 50%).
The proportions of patients with known PD-L1–positive
tumors were similar in the irAE+ and irAE− cohorts (26
of 36 [72.2%] for irAE+ vs 29 of 42 [69.0%] for irAE−;
P = .76). Patients were heavily pretreated with a median
of 2 prior lines of systemic therapy (range, 0-6) with or
without concurrent radiation in the definitive or palliative setting. The median duration of ICI therapy was
23 weeks among irAE+ patients and 12 weeks among
irAE− patients (P = .0006).
Among patients treated at the University of
Chicago, there were a total of 60 irAEs occurring in
49 of 108 patients (45.4%), with 8 of the 49 patients
(16.3%) experiencing more than 1 irAE. irAE types and
severities are displayed in Table 2, and the median time
to irAE incidence in the irAE+ group was 42 days (interquartile range, 19-84 days), with 2 patients developing irAEs beyond 22 weeks. The majority of irAEs were
dermatologic (21 of 60 [35.0%]), endocrine (14 of 60
[23.3%]), or musculoskeletal (15 of 60 [25.0%]). Low-
grade irAEs were common, with grade 1 and 2 events
3
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TABLE 2. Characteristics of Immune Adverse
Events

TABLE 3. Regression Analysis for Any Response

Characteristic

Covariate

Type of immune adverse event
Dermatologic
Pulmonary
Gastrointestinal
Endocrinopathy
Musculoskeletal
Ophthalmologic
Transaminitis
Type of immune adverse event by grade
1
Dermatologic
Pulmonary
Gastrointestinal
Endocrinopathy
Musculoskeletal
Ophthalmologic
Transaminitis
2
Dermatologic
Pulmonary
Gastrointestinal
Endocrinopathy
Musculoskeletal
Ophthalmologic
Transaminitis
3
Dermatologic
Pulmonary
Gastrointestinal
Endocrinopathy
Musculoskeletal
Ophthalmologic
Transaminitis

No. (% of Events)
21 (35.0)
1 (1.7)
1 (1.7)
14 (23.3)
15 (25.0)
2 (3.3)
6 (10.0)
41 (68.3)
16 (26.7)
0 (0)
0 (0)
10 (16.7)
13 (21.7)
0 (0)
2 (3.3)
14 (23.3)
4 (6.7)
0 (0)
0 (0)
4 (6.7)
1 (1.7)
1 (1.7)
4 (6.7)
5 (8.3)
1 (1.7)
1 (1.7)
1 (1.7)
0 (0)
1 (1.7)
1 (1.7)
0 (0)

representing 68.3% (41 of 60) and 23.3% (14 of 60) of
all irAEs, respectively. Grade 3 irAEs occurred in 10.2%
of the patients (5 of 49) and included arthralgias in bilateral shoulders (n = 1), uveitis (n = 1), macular rash
(n = 1), pneumonitis (n = 1), and colitis (n = 1). No
grade 4 or higher irAEs occurred in the University of
Chicago cohort.
Treatment Response

The results of univariate and multivariate analyses investigating factors associated with RECIST (version
1.1) responses for University of Chicago patients are
displayed in Table 3. The number of prior treatments
(odds ratio [OR], 0.52, 95% confidence interval [CI],
0.31-0.87; P = .01), age (OR, 1.04; 95% CI, 1.00-1.10;
P = .06), and irAE positivity (OR, 3.15; 95% CI, 1.16-
8.54; P = .02) were associated with the likelihood of
experiencing at least a partial response in the univariate
analysis. Specifically, patients in the irAE+ group had
an ORR of 30.6%, whereas it was 12.3% for irAE−
patients. In the multivariate analysis, irAE positivity
continued to be independently associated with a
4

Univariate
Age
Disease site
Other
Oropharynx
Sex
Male
Female
Ethnicity
White
Non-White
HPV-positive
No. of prior treatments
Tobacco use
PD-L1–positive
Immune adverse
event–positive
Multivariate
Age
No. of prior treatments
Immune adverse
event–positive

Odds Ratio

95% Confidence
Interval

P

1.04

1.00-1.10

.06

1.00 (reference)
1.11

0.43-2.86

.83

1.00 (reference)
1.2

0.41-3.48

.74

1.00 (reference)
0.39
0.98
0.52
1.63
1.11
3.15

0.08-1.85
0.17-5.82
0.31-0.87
0.54-4.93
0.36-3.41
1.16-8.54

.24
.98
.01
.39
.85
.02

1.04
0.49
3.23

0.99-1.09
0.28-0.85
1.12-9.29

.09
.01
.03

Abbreviations: HPV, human papillomavirus; PD-L1, programmed death ligand 1.

likelihood of response to ICI (OR, 3.23; 95% CI,
1.12-9.29; P = .03).
Survival Outcomes

The median follow-
up for all surviving University of
Chicago patients was 8.4 months (interquartile range,
4.7-24.0 months). Table 4 displays factors associated with
PFS. In the univariate analysis, age (hazard ratio [HR],
0.97; 95% CI, 0.96-0.99; P = .008), number of prior
treatments (HR, 1.20; 95% CI, 1.01-1.41; P = .03), and
irAE status (HR, 0.45; 95% CI, 0.28-0.70; P = .0005)
were associated with PFS, whereas tumor PD-L1 positivity was not (P = .63). Notably, experiencing 1 or more
irAEs was associated with a median PFS of 6.9 months in
contrast to 2.1 months for irAE− patients, as displayed
in Figure 1. Additionally, a multivariate analysis including variables significantly associated with PFS in the univariate analysis found irAE positivity to be independently
associated with improved PFS (HR, 0.49; 95% CI, 0.30-
0.78; P = .003).
Among University of Chicago patients, factors associated with OS are displayed in Table 5. Disease site
(oropharynx vs other, HR, 0.63; 95% CI, 0.39-0.99;
P = .05), number of prior treatments (HR, 1.21; 95%
CI, 1.01-1.43; P = .03), and irAE status (HR, 0.53;
95% CI, 0.33-0.85; P = .008) were associated with
OS in the univariate analysis, whereas PD-L1 positivity was not (P = .58). Notably, irAE+ patients experienced a median OS 5.7 months longer than that of
Cancer  
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TABLE 4. Regression Analysis for Progression-Free
Survival

Covariate
Univariate
Age
Disease site
Other
Oropharynx
Sex
Male
Female
Race/ethnicity
White
African American
Asian/Mideast
Indian
Hispanic/Latino
HPV-positive
No. of prior
treatments
Tobacco use
PD-L1–positive
Immune adverse
event–positive
Multivariate
Age
No. of prior
treatments
Immune adverse
event–positive

Hazard Ratio

95%
Confidence
Interval

P

0.97

0.96-0.99

.008

1.00 (reference)
1.07

0.69-1.65

.76

1.00 (reference)
1.10

0.65-1.79

.71

1.00 (reference)
0.95
1.09

0.44-1.80
0.27-2.95

1.16
0.80
1.20

0.19-3.73
0.37-2.01
1.01-1.41

.61
.03

0.68
1.14
0.45

0.43-1.10
0.67-2.02
0.28-0.70

.11
.63
.0005

0.98
1.23

0.96-1.00
1.03-1.44

.04
.02

0.49

0.30-0.78

.003

A

.99

W сϬ͘ϬϬϬϰ
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ϵ
Ϯϭ

ϰ
ϭϯ

Ϯ
ϴ

B

Ϯ
ϱ

W сϬ͘ϬϬϳ

Abbreviations: HPV, human papillomavirus; PD-L1, programmed death ligand 1.

irAE− patients (median, 12.5 months for irAE+ patients vs 6.8 months for irAE− patients) and continued
to experience significantly improved OS in the 22-week
landmark analysis (median, 25.3 months for irAE+
patients [n = 20] vs 13.4 months for irAE− patients
[n = 14]; P = .047), as displayed in Figure 1. Moreover,
experiencing 1 or more irAEs remained independently
associated with OS (HR, 0.49; 95% CI, 0.30-0.79;
P = .004) in a multivariate analysis.
Analyses investigating the association between
irAE type and grade and OS for University of Chicago
patients are displayed in Supporting Tables 1 and 2,
respectively. In a univariate Cox proportional hazards
regression, only dermatologic irAEs (HR, 0.38; 95%
CI, 0.19-0.76; P = .002), pulmonary irAEs (HR, 11.0;
95% CI, 0.60-58.7; P = .09), and endocrine-related
irAEs (HR, 0.47; 95% CI, 0.22-0.90; P = .02) were
associated with OS. Both dermatologic irAEs (HR,
0.42; 95% CI, 0.21-0.84; P = .007) and endocrine-
related irAEs (HR, 0.49; 95% CI, 0.24-0.99; P = .03)
remained associated with OS in a multivariate analysis
when dermatologic, endocrine-related, and pulmonary
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Figure 1. (A) Progression-free survival as a function of the irAE
status. (B) Overall survival as a function of the irAE status. (C)
Landmark analysis 22 weeks after the initiation of anti–PD-1
therapy for overall survival as a function of the irAE status. irAE
indicates immune-
related adverse event; PD-
1, programmed
death 1.
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TABLE 5. Regression Analysis for Overall Survival
Covariate
Univariate
Age
Disease site
Other
Oropharynx
Sex
Male
Female
Race/ethnicity
White
African American
Asian/Mideast
Indian
Hispanic/Latino
HPV-positive
No. of prior
treatments
Tobacco use
PD-L1–positive
Immune adverse
event–positive
Multivariate
Disease site
Other
Oropharynx
No. of prior
treatments
Immune adverse
event–positive

Hazard Ratio

95% Confidence
Interval

P

0.98

0.97-1.00

.13

1.00 (reference)
0.63

0.39-0.99

.05

1.00 (reference)
1.03

0.57-1.75

.93

1.00 (reference)
0.26
1.17

0.06-0.70
0.19-3.81

2.43
1.01
1.21

0.13-12.06
0.37-3.51
1.01-1.43

.99
.03

0.68
1.18
0.53

0.41-1.13
0.67-2.16
0.33-0.85

.13
.58
.008

1.00 (reference)
0.57
1.21

0.36-0.91
1.01-1.43

.02
.04

0.49

0.30-0.79

.004

.11

Abbreviations: HPV, human papillomavirus; PD-L1, programmed death ligand 1.

irAEs were included as covariates. Furthermore, there
was a significant association between grade 1 (HR,
0.46; 95% CI, 0.23-0.86; P = .01) and grade 2 irAEs
(HR, 0.52; 95% CI, 0.27-0.93; P = .03) and OS, but
there was no significant association for grade 3 irAEs
(HR, 1.02; 95% CI, 0.31-2.53; P = .97). Rapid development of an irAE ≤2 weeks from the initiation of ICI
was not statistically significantly associated with OS.
External Patient Cohort Results

Among the 47 patients receiving ICI at Providence
Cancer Institute, with a median follow-
up of
14.9 months (interquartile range, 10.4-27.4 months)
for surviving patients, the median age was 60 years,
with 85.1% being male, as displayed in Supporting
Table 3. Within this cohort, 19 irAEs occurred in 17
patients, with most being dermatologic (5 of 19 irAEs
[26.3%]) or pulmonary (3 of 19 irAEs [15.8%]) and
low grade (12 of 17 patients with the worst irAE
grade ≤ 2 [70.6%]), as detailed in Supporting Table 4.
Experiencing 1 or more irAEs was significantly associated with PFS (median PFS, 9.2 months for irAE+ vs
3.6 months for irAE−; P = .0002) and OS (median
OS, 36.4 months for irAE+ vs 8.2 months for irAE−;
6

P = .001), as displayed in Figure 2A,B, respectively.
Moreover, developing 1 or more irAEs remained independently associated with PFS (HR, 0.29; 95% CI,
0.13-0.59; P = .001) and OS (HR, 0.20; 95% CI,
0.07-0.50; P = .002) in multivariate survival analyses,
as displayed in Supporting Tables 5 and 6, respectively.
Finally, Supporting Table 7 demonstrates that the irAE
status was significantly associated with response in both
univariate (OR, 12.86; 95% CI, 2.77-59.66; P = .001)
and multivariate analyses (OR, 30.90; 95% CI, 3.08-
309.65; P = .004).
DISCUSSION
Within 2 separate cohorts of patients with recurrent/
metastatic HNC receiving ICI, experiencing 1 or more
irAEs was associated with significantly improved clinical
outcomes, including response, PFS, and OS. IrAEs were
common and occurred in 45.4% of patients (49 of 108)
treated at the University of Chicago and in 36.2% of patients (17 of 47) treated at Providence Cancer Institute.
Despite this high incidence, the vast majority of irAEs
were low grade, with grade 3 or higher irAEs occurring
in just 10 of 66 patients (15.2%) treated at both sites.
Furthermore, the most common irAEs were dermatologic,
musculoskeletal, or endocrine-related, with dermatologic
and endocrine-related irAEs having the strongest association with OS among University of Chicago patients.
Importantly, the association between irAE status and
OS persisted in a 22-week landmark analysis for patients
treated at the University of Chicago, and this mitigates
the likelihood that this association is confounded by differences in the duration of ICI according to the irAE status. Similar statistical results between groups of patients
receiving ICI at a different clinical facility strengthen the
conclusion that experiencing 1 or more irAEs in this setting is associated with favorable oncologic outcomes.
The association between 1 or more irAEs during
the receipt of ICI and improved oncologic outcomes
likely stems from the role of the PD-1/PD-L1 axis in the
maintenance of self-tolerance for normal tissues27 and
the potential for cross-reactivity among antigens on the
surface of tumor and nontumor cells.28 Importantly, the
development of irAEs is a potential surrogate for baseline
immune competence because both antitumor response
and the primarily T cell–driven pathogenesis of irAEs29
require a functional baseline endogenous immune response. Despite the postulated importance of baseline immune competence for generating a successful antitumor
response on ICI, barriers to an optimally functional endogenous immune system in patients with HNC include
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Figure 2. (A) Progression-free survival as a function of the irAE status for patients treated at Providence Cancer Institute. (B)
Overall survival as a function of the irAE status for patients treated at Providence Cancer Institute. irAE indicates immune-related
adverse event.

immunosuppression attributed to cancer itself and imparted by standard treatments such as cytotoxic chemotherapy/radiation.30 Although the importance of baseline
immune competence is just beginning to be understood
and predictive biomarkers are being explored,31 irAEs appear to preferentially develop in patients who have a systemic and intratumoral immunologic milieu primed for a
strong response to ICI as evidenced by the impressive prolongation of OS in irAE+ patients in this report. As such,
irAE+ patients may be an ideal candidate population for
the identification of novel, measurable pretreatment biomarkers of immune competence that could inform clinical trials investigating the role of immunomodulatory
agents in cancer care.
Interestingly, we found that dermatologic and
endocrine-
related irAEs were most strongly associated with improved OS among patients treated at the
University of Chicago, and this suggests that the irAE
type may modulate the prognostic association with OS.
Dermatologic irAEs have similarly been associated with
improved OS for patients with non–small cell lung cancer receiving nivolumab; however, a favorable association
with OS was not observed for endocrine-related irAEs in
the same cohort.15 Although this is contradictory to our
results, our ability to detect such an association between
OS and endocrine-related irAEs was likely markedly enhanced because of our higher relative number of patients
with this type of irAE in an HNC population (14 of 49
[28.6%] vs 11 of 134 [8%]). Additionally, specific types
of irAEs may be more or less prognostically useful in patients with different primary malignancies. For instance,
vitiligo and rash appear to be most prognostic for patients
receiving ICI for melanoma.11,17
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Just as the irAE type may influence the prognosis
with immunomodulatory therapy, low-grade irAEs but
not high-grade ones were associated with improved OS
in patients treated at the University of Chicago. Although
prior reports have suggested that grade 3 or higher irAEs
are prognostically favorable for a response and the median time to progression,12 the relatively low number of
patients in the University of Chicago cohort experiencing
grade 3 or higher irAEs (5 of 49) may have limited our
ability to find a similar favorable prognostic relationship
with OS. Furthermore, it is reasonable to hypothesize
that a low-level breach of self-tolerance induced in immunocompetent individuals receiving ICI may strike the
optimal balance between an enhanced antitumor effect
and increased competing mortality risks associated with
higher grade irAEs.
Our data add to the growing body of literature reporting the safety and efficacy of ICI in current clinical
practice. The rate of irAEs in patients treated at 2 separate clinical facilities for HNC is somewhat lower than
previously reported rates of approximately 70% for
mixed solid malignancies receiving immune checkpoint
blockade with anti–
PD-
1 or anti–
PD-
L1 agents.32
Specific subsets of irAEs, including dermatologic (21
of 60 [35.0%]) and endocrine-related irAEs (14 of 60
[23.3%]) at the University of Chicago, occurred somewhat more frequently than has been previously reported
in Checkmate 141 patients (15.7% for dermatologic
ones and 7.6% for endocrine-related ones)6 or pooled
KEYNOTE-012 patients (9% for rash and 10% for
hypothyroidism).33 One possible explanation for the
higher reported rate of any-
grade endocrine-
related
irAEs, including primarily thyroid dysfunction, may
7
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be the high proportion of patients in the University of
Chicago group receiving previous radiation (100 of 108
[92.6%]) in comparison with KEYNOTE-012 (146 of
196 [74%])33 because radiation to the thyroid gland for
primary HNC may predispose patients to this adverse
event.
Limitations to our study include its retrospective
nature and inclusion of patients with diverse characteristics primarily treated on protocol before the use of ICI
as standard of care in the setting of metastatic HNC.
Additionally, there is no consensus definition for irAEs,
and this makes comparisons of our experience with prior
reports difficult. Finally, we were unable to evaluate the
impact of irAE treatment with corticosteroids because
data related to corticosteroid use were not available.
Nevertheless, previous reports suggest that corticosteroid
use in patients receiving ICI may not affect the prognostic significance of the irAE status13 or adversely affect OS
or the time to treatment failure.34 Taken together, these
findings suggest that the prompt treatment of severe
irAEs with corticosteroids is safe, the treatment benefit is
robust, and corticosteroid use does not negate the highly
favorable association between the development of irAEs
and outcomes.
Overall, low-grade irAEs were common for patients
unselected for their PD-L1 status who were receiving ICI
for recurrent/metastatic HNC. Low-grade irAEs and, in
particular, dermatologic and endocrine-related irAEs were
most strongly associated with improved OS. Furthermore,
experiencing 1 or more irAEs of any grade was associated
with superior responses, PFS, and OS in 2 separate patient cohorts. The development of irAEs has a positive
prognostic association when patients are receiving ICI
for recurrent/metastatic HNC and as such likely reflects
immune competence. Future investigations should focus
on measurements of baseline immune competence and
strategies to modulate immune competence over time.
Also, research analyzing the likely complex relationship
between irAE management and prognosis is warranted
because the majority of patients receiving ICI will experience 1 or more irAEs.
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